CAMPBELL, Calif.--(BUSINESS WIRE)--Sadra Medical, a medical device firm dedicated to developing innovative new therapies for aortic valve disease, today announced the enrollment and treatment of four new patients in the second phase of its European Feasibility Study of the Sadra Lotus™ Valve System. The system is designed to enable physicians to replace a diseased aortic valve utilizing a less invasive approach, navigating the valve through the patient’s arteries using a catheter-based delivery system and thereby eliminating the need for an open chest surgical procedure. The company also announced that co-founder and board member, Fred Khosravi, has accepted the role of Chairman of the Board.
